The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis
Clinical Science · 2025
DOI: 10.1042/cs20245138 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Science, 2025. Verfasst von Simon G Royce und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Clayton, Victoria, 3800, Australia. Hauptthemen laut MEDLINE: Pyridones, Pulmonary Fibrosis, Receptor, Angiotensin, Type 2, Lung. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Angiotensin II AT2 receptor (AT2R) activation leads to significant anti-fibrotic and anti-inflammatory effects in diseased organs, which has led to clinical trial evaluation of the AT2R agonist, Compound 21 (C21), as a treatment for idiopathic pulmonary fibrosis (IPF). In this study, the anti-fibrotic effects of a more selective AT2R ligand, β-Pro7 angiotensin III (β-Pro7 Ang III), with >20,000-fold affinity for the AT2R over the AT1R, were compared with that of C21 or the currently used IPF medication, pirfenidone, in mice with bleomycin (BLM)-induced pulmonary fibrosis. Adult female BALB/c mice received a double intranasal instillation of BLM (20 mg/kg/day) seven days apart and were maintained until day 35, while control mice were instilled with saline (SAL) seven days apart and maintained for the same time period. Sub-groups of BLM-injured mice were then treated on day 28 with vehicle (SAL), C21 (0.3 mg/kg/day) or β-Pro7 Ang III (0.1 mg/kg/day) via seven-day subcutaneously implanted osmotic minipumps, or daily from days 28 to 35 via orally administered pirfenidone (100 mg/kg/day). At day-35 post-injury, measures of lung fibrosis and compliance were evaluated. Compared with their SAL-instilled counterparts, SAL-treated BLM-injured mice presented with a significantly increased lung Ashcroft score, Masson’s trichrome-stained and second harmonics generation-measured fibrosis, myofibroblast accumulation, and TGF-β1 expression, but reduced lung dynamic compliance at day-35 post-injury. While all treatments evaluated attenuated the BLM-induced lung myofibroblast accumulation and TGF-β1 expression, AT2R stimulation, but not pirfenidone, attenuated lung collagen deposition after seven days. β-Pro7 Ang III also significantly restored lung compliance and promoted collagen-degrading matrix metalloproteinase-2 activity. These findings highlighted the therapeutic value of selectively targeting the AT2R for treating IPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Clayton, Victoria, 3800, Australia.
ORCID-Profile: Robert E Widdop, Chrishan S Samuel
Zitieren
APA
Royce, S. G., Erdem, C., Mao, W., Wang, Y., Del Borgo, M. P., Widdop, R. E., & Samuel, C. S. (2025). The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis. Clinical Science. https://doi.org/10.1042/cs20245138
Vancouver
Royce SG, Erdem C, Mao W, Wang Y, Del Borgo MP, Widdop RE, et al. The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis. Clinical Science. 2025. doi:10.1042/cs20245138
BibTeX
@article{Royce2025,
author = {Royce, Simon G and Erdem, Cem and Mao, WeiYi and Wang, Yan and Del Borgo, Mark P and Widdop, Robert E and Samuel, Chrishan S},
title = {The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis},
journal = {Clinical Science},
year = {2025},
doi = {10.1042/cs20245138}
}
EUVIMED